Evaluation and Management of Breast Pain

Mayo Clinic Proceedings

Volumn 79, Issue 3, 2004, Pages 353-372

  Smith, Robin L ^a   Pruthi, Sandhya ^a   Fitzpatrick, Lorraine A ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANXIOLYTIC AGENT; BROMOCRIPTINE; BUSERELIN; DANAZOL; DICLOFENAC; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN; GESTAGEN; GESTRINONE; GONADORELIN AGONIST; GOSERELIN; LISURIDE; LYNESTRENOL; MEDROXYPROGESTERONE ACETATE; NEUROLEPTIC AGENT; NIMESULIDE; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PIROXICAM; PRIMROSE OIL; PROGESTERONE; PROMEGESTONE; QUINAGOLIDE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNINDEXED DRUG; VITEX AGNUS CASTUS EXTRACT;

ACNE; ANXIETY; CANCER RISK; CLINICAL FEATURE; CLINICAL TRIAL; CYCLIC MASTALGIA; DAILY LIFE ACTIVITY; DEEP VEIN THROMBOSIS; DEPRESSION; DIET RESTRICTION; DIET THERAPY; ENDOMETRIUM CANCER; EVALUATION; EXTRAMAMMARY PAIN; FATIGUE; GALACTORRHEA; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HAIR LOSS; HEADACHE; HOT FLUSH; HUMAN; IRRITABILITY; LIBIDO DISORDER; MASTALGIA; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; NAUSEA; NONCYCLIC MASTALGIA; PAIN; RASH; REVIEW; SYMPTOM; THORAX WALL; VAGINA DISCHARGE; VAGINAL DRYNESS; VITAMIN INTAKE; VITEX AGNUS CASTUS; VOMITING; WEIGHT GAIN;

EID: 1442355649     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/79.3.353     Document Type: Review

References (224)

1. Cooper A. Illustrations of the Diseases of the Breast, Part 1. London, England: Longman, Rees, Orme, Brown & Green; 1829.
2. Grimm K, Fritsche E. Reduction of breasts: Hans Schaller and the first mammaplasty in 1561 [in German]. Handchir Mikrochir Plast Chir. 2000;32:316-320.
3. BRIDGE Study Group. The presentation and management of breast symptoms in general practice in South Wales. Br J Gen Pract. 1999;49:811-812.
4. Mansel RE. ABC of breast disease: breast pain. BMJ. 1994;309:866-868.
5. Roberts MM, Elton RA, Robinson SE, French K. Consultations for breast disease in general practice and hospital referral patterns. Br J Surg. 1987;74:1020-1022.
6. Nichols S, Waters WE, Wheeler MJ. Management of female breast disease by Southampton general practitioners. BMJ. 1980;281:1450-1453.
7. Bywaters JL. The incidence and management of female breast disease in a general practice. J R Coll Gen Pract. 1977;27:353-357.
8. Barton MB, Elmore JG, Fletcher SW. Breast symptoms among women enrolled in a health maintenance organization: frequency, evaluation, and outcome. Ann Intern Med. 1999;130:651-657.
9. Ader DN, Browne MW. Prevalence and impact of cyclic mastalgia in a United States clinic-based sample. Am J Obstet Gynecol. 1997;177:126-132.
10. Black WC, Nease RF Jr, Tosteson AN. Perceptions of breast cancer risk and screening effectiveness in women younger than 50 years of age. J Natl Cancer Inst. 1995;87:720-731.
11. Maddox PR, Mansel RE. Management of breast pain and nodularity. World J Surg. 1989;13:699-705.
12. Braunstein GD. Gynecomastia. In: Harris JR, Lippman ME, Morrow M, Hellman S, eds. Diseases of the Breast. Philadelphia, Pa: Lippincott-Raven; 1996:54-60.
13. Pitt B, Zannad F, Remme WJ, et al, Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
14. BeLieu RM. Mastodynia. Obstet Gynecol Clin North Am. 1994; 21:461-477.
15. Dixon JM. Managing breast pain. Practitioner. 1999; 243:484-486,488-489,491.
16. Morrow M. The evaluation of common breast problems. Am Fam Physician. 2000;61:2371-2378, 2385.
17. Klimberg VS. Etiology and management of breast pain. In: Harris JR, Lippman ME, Morrow M, Hellman S, eds. Diseases of the Breast. Philadelphia, Pa: Lippincott-Raven; 1996:99-106.
18. Gateley CA, Mansel RE. Management of cyclical breast pain. Br J Hosp Med. 1990;43:330-332.
19. Steinbrunn BS, Zera RT, Rodriguez JL. Mastalgia: tailoring treatment to type of breast pain. Postgrad Med. 1997;102:183-184, 187-189,193-194.
20. Faiz O, Fentiman IS. Management of breast pain. Int J Clin Pract. 2000;54:228-232.
21. Davies EL, Gateley CA, Miers M, Mansel RE. The long-term course of mastalgia. J R Soc Med. 1998;91:462-464.
22. Gateley CA, Miers M, Mansel RE, Hughes LE. Drug treatments for mastalgia: 17 years experience in the Cardiff Mastalgia Clinic. J R Soc Med. 1992;85:12-15.
23. Breast pain: mastalgia is common but often manageable. Mayo Clin Health Lett. April 2000;18:6.
24. McFayden IJ, Forrest AP, Chetty U, Raab G. Cyclical breast pain - some observations and the difficulties in treatment. Br J Clin Pract. Autumn 1992;46:161-164.
25. Ader DN, South-Paul J, Adera T, Deuster PA. Cyclical mastalgia: prevalence and associated health and behavioral factors. J Psychosom Obstet Gynecol. 2001;22:71-76.
26. Goodwin PJ, Miller A, Del Giudice ME, Ritchie K. Breast health and associated premenstrual symptoms in women with severe cyclic mastopathy. Am J Obstet Gynecol. 1997;176:998-1005.
27. Ader DN, Shriver CD. Cyclical mastalgia: prevalence and impact in an outpatient breast clinic sample. J Am Coll Surg. 1997;185: 466-470.
28. Preece PE, Mansel RE, Bolton PM, Hughes LM, Baum M, Gravelle IH. Clinical syndromes of mastalgia. Lancet. 1976;2: 670-673.
29. Watt-Boolsen S, Emus HC, Junge J. Fibrocystic disease and mastalgia: a histological and enzyme-histochemical study. Dan Med Bull. 1982;29:252-254.
30. Jorgensen J, Watt-Boolsen S. Cyclical mastalgia and breast pathology. Acta Chir Scand. 1985;151:319-321.
31. Love SM, Gelman RS, Silen W. Fibrocystic "disease" of the breast - a nondisease? N Engl J Med. 1982;307:1010-1014.
32. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985;312:146-151.
33. Hughes LE. Benign breast disorders - introduction: fibrocystic disease? nondisease? or ANDI? World J Surg. 1989;13:667-668.
34. Marchant DJ. Benign breast disease. Obstet Gynecol Clin North Am. 2002;29:1-20.
35. Ramakrishnan R, Werbeck J, Khurana KK, Khan SA. Expression of interleukin-6 and tumor necrosis factor α and histopathologic findings in painful and nonpainful breast tissue. Breast J. 2003; 9:91-97.
36. Andrews WC. Hormonal management of fibrocystic disease of the breast. J Reprod Med. 1990;35(1, suppl):87-90.
37. Dogliotti L, Orlandi F, Angeli A. The endocrine basis of benign breast disorders. World J Surg. 1989;13:674-679.
38. Walsh PV, McDicken IW, Bulbrook RD, Moore JW, Taylor WH, George WD. Serum oestradiol-17β and prolactin concentrations during the luteal phase in women with benign breast disease. Eur J Cancer Clin Oncol. 1984;20:1345-1351.
39. Sitruk-Ware LR, Sterkers N, Mowszowicz I, Mauvais-Jarvis P. Inadequate corpus luteal function in women with benign breast diseases. J Clin Endocrinol Metab. 1977;44:771-774.
40. Watt-Boolsen S, Andersen AN, Blitchert-Toft M. Serum prolactin and oestradiol levels in women with cyclical mastalgia. Horm Metab Res. 1981;13:700-702.
41. Kumar S, Mansel RE, Scanlon MF, et al. Altered responses of prolactin, luteinizing hormone and follicle stimulating hormone secretion to thyrotropin releasing hormone/gonadotropin releasing hormone stimulation in cyclical mastalgia. Br J Surg. 1984;71: 870-873.
42. Boyd NF, McGuire V, Shannon P, et al. Effect of a low-fat high-carbohydrate diet on symptoms of cyclical mastopathy. Lancet. 1988;2:128-132.
43. Ayers JW, Gidwani GP. The "luteal breast": hormonal and sonographic investigation of benign breast disease in patients with cyclic mastalgia. Fertil Steril. 1983;40:779-784.
44. England PC, Skinner LG, Cottrell KM, Sellwood RA. Sex hormones in breast disease. Br J Surg. 1975;62:806-809.
45. Gorins A, Cordray JP. Hormonal profile of benign breast disease and premenstrual mastodynia. Eur J Gynaecol Oncol. 1984;5:1-10.
46. Sitruk-Ware R, Sterkers N, Mauvais-Jarvis P. Benign breast disease, I: hormonal investigation. Obstet Gynecol. 1979;53:457-460.
47. Walsh PV, Bulbrook RD, Stell PM, Wang DY, McDicken IW, George WD. Serum progesterone concentration during the luteal phase in women with benign breast disease. Eur J Cancer Clin Oncol. 1984;20:1339-1343.
48. Kumar S, Mansel RE, Wilson DW, et al. Daily salivary progesterone levels in cyclical mastalgia patients and their controls. Br J Surg. 1986;73:260-263.
49. Ecochard R, Marret H, Rabilloud M, Boehringer H, Mathieu C, Guerin JF. Gonadotropin level abnormalities in women with cyclic mastalgia. Eur J Obstet Gynecol Reprod Biol. 2001;94:92-96.
50. Cole EN, Sellwood RA, England PC, Griffiths K. Serum prolactin concentrations in benign breast disease throughout the menstrual cycle. Eur J Cancer. 1977;13:597-603.
51. Graziottin A, Sopracordevole F, Velasco M, Grella PV. Plasma prolactin in women with mastodynia. Clin Exp Obstet Gynecol. 1984;11:113-116.
52. Kumar S, Mansel RE, Hughes LE, et al. Prolactin response to thyrotropin-releasing hormone stimulation and dopaminergic inhibition in benign breast disease. Cancer. 1984;53:1311-1315.
53. Parlati E, Travaglini A, Liberale I, Menini E, Dell'Acqua S. Hormonal profile in benign breast disease: endocrine status of cyclical mastalgia patients. J Endocrinol Invest. 1988;11:679-683.
54. Watt-Boolsen S, Eskildsen PC, Blaehr H. Release of prolactin, thyrotropin, and growth hormone in women with cyclical mastalgia and fibrocystic disease of the breast. Cancer. 1985;56:500-502.
55. Horrobin DF. The effects of gamma-linolenic acid on breast pain and diabetic neuropathy: possible non-eicosanoid mechanisms. Prostaglandins Leukot Essent Fatty Acids. 1993;48:101-104.
56. Sharma AK, Mishra SK, Salila M, Ramesh V, Bal S. Cyclical mastalgia - is it a manifestation of aberration in lipid metabolism? Indian J Physiol Pharmacol. 1994;38:267-271.
57. Sprecher H. Biochemistry of essential fatty acids. Prog Lipid Res. 1981;20:13-22.
58. Milligan D, Drife JO, Short RV. Changes in breast volume during normal menstrual cycle and after oral contraceptives. BMJ. 1975;4:494-496.
59. Preece PE, Richards AR, Owen GM, Hughes LE. Mastalgia and total body water. BMJ. 1975;4:498-500.
60. Atkins HJB. Chronic mastitis. Lancet. 1938;1:707-712.
61. Preece PE, Mansel RE, Hughes LE. Mastalgia: psychoneurosis or organic disease? BMJ. 1978;1:29-30.
62. Ramirez AJ, Jarrett SR, Hamed H, Smith P, Fentiman IS. Psychosocial adjustment of women with mastalgia. Breast. 1995;4:48-51.
63. Fox H, Walker LG, Heys SD, Ah-See AK, Eremin O. Are patients with mastalgia anxious, and does relaxation therapy help? Breast. 1997;6:138-142.
64. Jenkins PL, Jamil N, Gateley C, Mansel RE. Psychiatric illness in patients with severe treatment-resistant mastalgia. Gen Hosp Psychiatry. 1993;15:55-57.
65. Colegrave S, Holcombe C, Salmon P. Psychological characteristics of women presenting with breast pain. J Psychosom Res. 2001;50:303-307.
66. Downey HM, Deadman JM, Davis C, Leinster SJ. Psychological characteristics of women with cyclical mastalgia. Breast Dis. 1993;6:99-105.
67. Klock SC. Psychological aspects of women's reproductive health. In: Ryan KJ, Berkowitz RS, Barbieri RL, Dunaif A, eds. Kistner's Gynecology and Women's Health. 7th ed. St Louis, Mo: Mosby; 1999:519-539.
68. Tavaf-Motamen H, Ader DN, Browne MW, Shriver CD. Clinical evaluation of mastalgia. Arch Surg. 1998;133:211-213.
69. Ader DN, Shriver CD, Browne MW. Cyclical mastalgia: premenstrual syndrome or recurrent pain disorder? J Psychosom Obstet Gynaecol. 1999;20:198-202.
70. Goodwin PJ, DeBoer G, Clark RM, et al. Cyclical mastopathy and premenopausal breast cancer risk: results of a case-control study. Breast Cancer Res Treat. 1995;33:63-73.
71. Plu-Bureau G, Thalabard JC, Sitruk-Ware R, Asselain B, Mauvais-Jarvis P. Cyclical mastalgia as a marker of breast cancer susceptibility: results of a case-control study among French women. Br J Cancer. 1992;65:945-949.
72. Davies GC, Huster WJ, Lu Y, Plouffe L Jr, Lakshmanan M. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol. 1999;93:558-565.
73. McNicholas MM, Heneghan JP, Milner MH, Tunney T, Hourihane JB, MacErlaine DP. Pain and increased mammographic density in women receiving hormone replacement therapy: a prospective study. AJR Am J Roentgenol. 1994;163:311-315.
74. Lundstrom E, Wilczek B, von Palffy Z, Soderqvist G, von Schoultz B. Mammographic breast density during hormone replacement therapy: differences according to treatment. Am J Obstet Gynecol. 1999;181:348-352.
75. Colacurci N, Mele D, De Franciscis P, Costa V, Fortunato N, De Seta L. Effects of tibolone on the breast. Eur J Obstet Gynecol Reprod Biol. 1998;80:235-238.
76. Peters F, Diemer P, Mecks O, Behnken LJ. Severity of mastalgia in relation to milk duct dilatation. Obstet Gynecol. 2003;101:54-60.
77. Conry C. Evaluation of a breast complaint: is it cancer? Am Fam Physician. 1994;49:445-450,453-454.
78. Preece PE, Baum M, Mansel RE, et al. Importance of mastalgia in operable breast cancer. BMJ (Clin Res Ed). 1982;284:1299-1300.
79. Smallwood JA, Kye DA, Taylor I. Mastalgia: is this commonly associated with operable breast cancer? Ann R Coll Surg Engl. 1986;68:262-263.
80. Fariselli G, Lepera P, Viganotti G, Martelli G, Bandieramonte G, Di Pietro S. Localized mastalgia as presenting symptom in breast cancer. Eur J Surg Oncol. 1988;14:213-215.
81. Lumachi F, Ermani M, Brandes AA, et al. Breast complaints and risk of breast cancer: population-based study of 2,879 self-selected women and long-term follow-up. Biomed Pharmacother. 2002;56:88-92.
82. Benson EA. Mastalgia: is this commonly associated with operable breast cancer [letter]. Ann R Coll Surg Engl. 1987;69:87.
83. Khan SA, Apkarian AV. Mastalgia and breast cancer: a protective association? [published correction appears in Cancer Detect Prev. 2003;27:82]. Cancer Detect Prev. 2002;26:192-196.
84. Khan SA, Apkarian AV. Mastalgia and breast cancer: a protective association? [published correction appears in Cancer Detect Prev. 2003;27:82]. Cancer Detect Prev. 2002;26:192-196.
85. Duijm LE, Guit GL, Hendriks JH, Zaat JO, Mali WP. Value of breast imaging in women with painful breasts: observational follow up study. BMJ. 1998;317:1492-1495.
86. Wallace MS, Wallace AM, Lee J, Dobke MK. Pain after breast surgery: a survey of 282 women. Pain. 1996;66:195-205.
87. Kwekkeboom K. Postmastectomy pain syndromes. Cancer Nurs. 1996;19:37-43.
88. Kroner K, Krebs B, Skov J, Jorgensen HS. Immediate and long-term phantom breast syndrome after mastectomy: incidence, clinical characteristics and relationship to pre-mastectomy breast pain. Pain. 1989;36:327-334.
89. Maddox PR, Harrison BJ, Mansel RE, Hughes LE. Non-cyclical mastalgia: an improved classification and treatment. Br J Surg. 1989;76:901-904.
90. Fam AG. Approach to musculoskeletal chest wall pain. Prim Care. 1988;15:767-782.
91. Wise CM. Chest wall syndromes [editorial]. Curr Opin Rheumatol. 1994;6:197-202.
92. Gregory PL, Biswas AC, Batt ME. Musculoskeletal problems of the chest wall in athletes. Sports Med. 2002;32:235-250.
93. Disla E, Rhim HR, Reddy A, Karten I, Taranta A. Costochondritis: a prospective analysis in an emergency department setting. Arch Intern Med. 1994;154:2466-2469.
94. Leung JW, Kornguth PJ, Gotway MB. Utility of targeted sonography in the evaluation of focal breast pain. J Ultrasound Med. 2002;21:521-526.
95. Khan SA, Apkarian AV. The characteristics of cyclical and non-cyclical mastalgia: a prospective study using a modified McGill Pain Questionnaire. Breast Cancer Res Treat. 2002;75:147-157.
96. Fentiman IS, Caleffi M, Hamed H, Chaudary MA. Dosage and duration of tamoxifen treatment for mastalgia: a controlled trial. Br J Surg. 1988;75:845-846.
97. Fentiman IS. Management of breast pain. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. 2nd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2000:57-62.
98. Millett AV, Dirbas FM. Clinical management of breast pain: a review. Obstet Gynecol Surv. 2002;57:451-461.
99. Ashley B. Mastalgia. Lippincotts Prim Care Pract. 1998;2:189-193.
100. O'Grady LF. The painful breast. In: O'Grady LF, Lindfors KK, Howel LP, Rippon MB, eds. A Practical Approach to Breast Disease. Boston, Mass: Little, Brown and Company; 1995:119-130.
101. Vaidyanathan L, Barnard K, Elnicki DM. Benign breast disease: when to treat, when to reassure, when to refer. Cleve Clin J Med. 2002;69:425-432.
102. Wilson MC, Sellwood RA. Therapeutic value of a supporting brassiere in mastodynia. BMJ. 1976;2:90.
103. Mason BR, Page KA, Fallon K. An analysis of movement and discomfort of the female breast during exercise and the effects of breast support in three cases. J Sci Med Sport. 1999;2:134-144.
104. Page KA, Steele JR. Breast motion and sports brassiere design: implications for future research. Sports Med. 1999;27:205-211.
105. Proctor DS. Ultrasound therapy in the treatment of persistent breast pain [letter]. S Afr Med J. 1984;65:912.
106. Horner NK, Lampe JW. Potential mechanisms of diet therapy for fibrocystic breast conditions show inadequate evidence of effectiveness. J Am Diet Assoc. 2000;100:1368-1380.
107. Goodwin PJ, Miller A, Del Giudice ME, Singer W, Connelly P, Ritchie JW. Elevated high-density lipoprotein cholesterol and dietary fat intake in women with cyclic mastopathy. Am J Obstet Gynecol. 1998;179:430-437.
108. Rose DP, Boyar A, Haley N, Cohen C, Lahti H, Strong LE. Low fat diet in fibrocystic disease of the breast with cyclical mastalgia: a feasibility study [abstract]. Am J Clin Nutr. 1985;41:856.
109. Prentice R, Thompson D, Clifford C, Gorbach S, Goldin B, Byar D, Women's Health Trial Study Group. Dietary fat reduction and plasma estradiol concentration in healthy postmenopausal women. J Natl Cancer Inst. 1990;82:129-134.
110. Boyar AP, Rose DP, Wynder EL. Recommendations for the prevention of chronic disease: the application for breast disease. Am J Clin Nutr. 1988;48(3, suppl):896-900.
111. Rose DP, Boyar AP, Cohen C, Strong LE. Effect of a low-fat diet on hormone levels in women with cystic breast disease, I: serum steroids and gonadotropins. J Natl Cancer Inst. 1987;78:623-626.
112. Boyd NF, Greenberg C, Lockwood G, et al, Canadian Diet and Breast Cancer Prevention Study Group. Effects at two years of a low-fat, high-carbohydrate diet on radiologic features of the breast: results from a randomized trial. J Natl Cancer Inst. 1997; 89:488-496.
113. Hu FB, Willett WC. Optimal diets for prevention of coronary heart disease. JAMA. 2002;288:2569-2578.
114. Levinson W, Dunn PM. Nonassociation of caffeine and fibrocystic breast disease. Arch Intern Med. 1986;146:1773-1775.
115. Minton JP, Abou-Issa H, Reiches N, Roseman JM. Clinical and biochemical studies on methylxanthine-related fibrocystic breast disease. Surgery. 1981;90:299-304.
116. Ernster VL, Mason L, Goodson WH, et al. Effects of caffeine-free diet on benign breast disease: a randomized trial. Surgery. 1982; 91:263-267.
117. Hindi-Alexander MC, Zielezny MA, Montes N, et al. Theophylline and fibrocystic breast disease. J Allergy Clin Immunol. 1985;75: 709-715.
118. Brooks PG, Gart S, Heldfond AJ, Margolin ML, Allen AS. Measuring the effect of caffeine restriction on fibrocystic breast disease: the role of graphic stress telethermometry as an objective monitor of disease. J Reprod Med. 1981;26:279-282.
119. La Vecchia C, Franceschi S, Parazzini F, et al. Benign breast disease and consumption of beverages containing methylxanthines. J Natl Cancer Inst. 1985;74:995-1000.
120. Boyle CA, Berkowitz GS, LiVolsi VA, et al. Caffeine consumption and fibrocystic breast disease: a case-control epidemiologic study. J Natl Cancer Inst. 1984;72:1015-1019.
121. Allen SS, Froberg DG. The effect of decreased caffeine consumption on benign proliferative breast disease: a randomized clinical trial. Surgery. 1987;101:720-730.
122. Lubin R, Ron E, Wax Y, Black M, Funaro M, Shitrit A. A case-control study of caffeine and methylxanthines in benign breast disease. JAMA. 1985;253:2388-2392.
123. Marshall J, Graham S, Swanson M. Caffeine consumption and benign breast disease: a case-control comparison. Am J Public Health. 1982;72:610-612.
124. Lawson DH, Jick H, Rothman KJ. Coffee and tea consumption and breast disease. Surgery. 1981;90:801-803.
125. Parazzini F, La Vecchia C, Riundi R, Pampallona S, Regallo M, Scanni A. Methylxanthine, alcohol-free diet and fibrocystic breast disease: a factorial clinical trial. Surgery. 1986;99:576-581.
126. Minton JP, Abou-Issa H. Nonendocrine theories of the etiology of benign breast disease. World J Surg. 1989;13:680-684.
127. Ferrini RL, Barrett-Connor E. Caffeine intake and endogenous sex steroid levels in postmenopausal women: the Rancho Bernardo Study. Am J Epidemiol. 1996;144:642-644.
128. Pye JK, Mansel RE, Hughes LE. Clinical experience of drug treatments for mastalgia. Lancet. 1985;2:373-377.
129. Renwick S. Modern management of benign mammary dysplasia. Med J Aust. 1979;1:562-566.
130. Smallwood J, Ah-Kye D, Taylor I. Vitamin B6 in the treatment of pre-menstrual mastalgia. Br J Clin Pract. 1986;40:532-533.
131. Santamaria LA, Santamaria AB. Cancer chemoprevention by supplemental carotenoids and synergism with retinol in mastodynia treatment. Med Oncol Tumor Pharmacother. 1990;7:153-167.
132. Abrams AA. Use of vitamin E in chronic cystic mastitis [letter]. N Engl J Med. 1965;272:1080-1081.
133. Solomon D, Strummer D, Nair PP. Relationship between vitamin E and urinary excretion of ketosteroid fractions in cystic mastitis. Ann N Y Acad Sci. 1972;203:103-110.
134. Sundaram GS, London R, Manimekalai S, Nair PP, Goldstein P. Alpha-tocopherol and serum lipoproteins. Lipids. 1981;16:223-227.
135. Ernster VL, Goodson WH III, Hunt TK, Petrakis NL, Sickles EA, Miike R. Vitamin E and benign breast "disease": a double-blind, randomized clinical trial. Surgery. 1985;97:490-494.
136. Meyer EC, Sommers DK, Reitz CJ, Mentis H. Vitamin E and benign breast disease. Surgery. 1990;107:549-551.
137. London RS, Sundaram GS, Murphy L, Manimekalai S, Reynolds M, Goldstein PJ. The effect of vitamin E on mammary dysplasia: a double-blind study. Obstet Gynecol. 1985;65:104-106.
138. Goodwin PJ, Neelam M, Boyd NF. Cyclical mastopathy: a critical review of therapy. Br J Surg. 1988;75:837-844.
139. Fentiman IS. Mastalgia mostly merits masterly inactivity [editorial]. Br J Clin Pract. Autumn 1992;46:158.
140. Holland PA, Gateley CA. Drug therapy for mastalgia: what are the options? Drugs. 1994;48:709-716.
141. Norlock FE. Benign breast pain in women: a practical approach to evaluation and treatment. J Am Med Womens Assoc. Spring 2002;57:85-90.
142. Pashby NL, Mansel RE, Hughes LE, Hanslip J, Preece PE. A clinical trial of evening primrose oil in mastalgia [abstract]. Br J Surg. 1981;68:801. Abstract 1.
143. Preece PE, Hanslip JI, Gilbert L, et al. Evening primrose oil (efamol) for mastalgia. In: Horrobin DF, ed. Clinical Uses of Essential Fatty Acids. Montreal, Quebec: Eden Press; 1982:147-154.
144. Wetzig NR. Mastalgia: a 3 year Australian study. Aust N Z J Surg. 1994;64:329-331.
145. Cheung KL. Management of cyclical mastalgia in oriental women: pioneer experience of using gamolenic acid (Efamast) in Asia. Aust N Z J Surg. 1999;69:492-494.
146. Blommers J, de Lange-De Klerk ES, Kuik DJ, Bezemer PD, Meijer S. Evening primrose oil and fish oil for severe chronic mastalgia: a randomized, double-blind, controlled trial. Am J Obstet Gynecol. 2002;187:1389-1394.
147. Campbell EM, Peterkin D, O'Grady K, Sanson-Fisher R. Premenstrual symptoms in general practice patients: prevalence and treatment. J Reprod Med. 1997;42:637-646.
148. Hardy ML. Herbs of special interest to women. J Am Pharm Assoc (Wash). 2000;40:234-242.
149. Khoo SK, Munro C, Battistutta D. Evening primrose oil and treatment of premenstrual syndrome. Med J Aust. 1990;153:189-192.
150. Brush MG. Efamol (evening primrose oil) in the treatment of the premenstrual syndrome. In: Horrobin DF, ed. Clinical Uses of Essential Fatty Acids. Montreal, Quebec: Eden Press; 1982:155-161.
151. Puolakka J, Makarainen L, Viinikka L, Ylikorkala O. Biochemical and clinical effects of treating the premenstrual syndrome with prostaglandin synthesis precursors. J Reprod Med. 1985;30:149-153.
152. Horrobin DF. The role of essential fatty acids and prostaglandins in the premenstrual syndrome. J Reprod Med. 1983;28:465-468.
153. Gateley CA, Maddox PR, Pritchard GA, et al. Plasma fatty acid profiles in benign breast disorders. Br J Surg. 1992;79:407-409.
154. Miller LG. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med. 1998;158:2200-2211.
155. Vincent A, Fitzpatrick LA. Soy isoflavones: are they useful in menopause? Mayo Clin Proc. 2000;75:1174-1184.
156. Cassidy A, Bingham S, Setchell KD. Biological effects of a diet of soy protein rich in isoflavones on the menstrual cycle of premenopausal women. Am J Clin Nutr. 1994;60:333-340.
157. Nagata C, Kabuto M, Kurisu Y, Shimizu H. Decreased serum estradiol concentration associated with high dietary intake of soy products in premenopausal Japanese women. Nutr Cancer. 1997;29:228-233.
158. McMichael-Phillips DF, Harding C, et al. Effects of soy-protein supplementation on epithelial proliferation in the histologically normal human breast. Am J Clin Nutr. 1998;68(6, suppl):1431S-1435S.
159. Petrakis NL, Barnes S, King EB, et al. Stimulatory influence of soy protein isolate on breast secretion in pre- and postmenopausal women. Cancer Epidemiol Biomarkers Prev. 1996;5:785-794.
160. Hargreaves DF, Potten CS, Harding C, et al. Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. J Clin Endocrinol Metab. 1999;84:4017-4024.
161. Loch EG, Selle H, Boblitz N. Treatment of premenstrual syndrome with a phytopharmaceutical formulation containing Vitex agnus castus. J Womens Health Gend Based Med. 2000;9:315-320.
162. Wuttke W, Jarry H, Christoffel V, Spengler B, Seidlova-Wuttke D. Chaste tree (Vitex agnus-castus) - pharmacology and clinical indications. Phytomedicine. 2003;10:348-357.
163. Palmer BV, Montgomery AC, Monteiro JC. Gin Seng and mastalgia [letter]. BMJ. 1978;1:1284.
164. Gabbrielli G, Binazzi P, Scaricabarozzi I, Massi GB. Nimesulide in the treatment of mastalgia. Drugs. 1993;46(suppl 1):137-139.
165. Irving AD, Morrison SL. Effectiveness of topical non-steroidal anti-inflammatory drugs in the management of breast pain. J R Coll Surg Edinb. 1998;43:158-159.
166. Colak T, Ipek T, Kanik A, Ogetman Z, Aydin S. Efficacy of topical nonsteroidal antiinflammatory drugs in mastalgia treatment. J Am Coll Surg. 2003;196:525-530.
167. Gateley CA, Maddox PR, Mansel RE, Hughes LE. Mastalgia refractory to drug treatment. Br J Surg. 1990;77:1110-1112.
168. Coney P, Washenik K, Langley RG, DiGiovanna JJ, Harrison DD. Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials. Contraception. 2001;63:297-302.
169. Graham CA, Sherwin BB. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res. 1992;36:257-266.
170. Bancroft J, Rennie D. The impact of oral contraceptives on the experience of perimenopausal mood, clumsiness, food craving and other symptoms. J Psychosom Res. 1993;37:195-202.
171. Euhus DM, Uyehara C. Influence of parenteral progesterones on the prevalence and severity of mastalgia in premenopausal women: a multi-institutional cross-sectional study. J Am Coll Surg. 1997;184:596-604.
172. Uzan S, Denis C, Pomi V, Varin C. Double-blind trial of promegestone (R 5020) and lynestrenol in the treatment of benign breast disease. Eur J Obstet Gynecol Reprod Biol. 1992;43:219-227.
173. Colin C, Gaspard U, Lambotte R. Relationship of mastodynia with its endocrine environment and treatment in a double blind trial with lynestrenol. Arch Gynakol. 1978;225:7-13.
174. Winkler UH, Schindler AE, Brinkmann US, Ebert C, Oberhoff C. Cyclic progestin therapy for the management of mastopathy and mastodynia. Gynecol Endocrinol. 2001;15(suppl 6):37-43.
175. Maddox PR, Harrison BJ, Horrobin JM, et al. A randomised controlled trial of medroxyprogesterone acetate in mastalgia. Ann R Coll Surg Engl. 1990;72:71-76.
176. Nappi C, Affinito P, Di Carlo C, Esposito G, Montemagno U. Double-blind controlled trial of progesterone vaginal cream treatment for cyclical mastodynia in women with benign breast disease. J Endocrinol Invest. 1992;15:801-806.
177. McFadyen IJ, Raab GM, Macintyre CC, Forrest AP. Progesterone cream for cyclic breast pain. BMJ. 1989;298:931.
178. Mansel RE, Wisbey JR, Hughes LE. Controlled trial of the antigonadotropin danazol in painful nodular benign breast disease. Lancet. 1982;1:928-930.
179. Ramsey-Stewart G. The treatment of symptomatic benign breast disease with danazol. Aust N Z J Obstet Gynaecol. 1988;28:299-304.
180. Watts JF, Butt WR, Logan Edwards R. A clinical trial using danazol for the treatment of premenstrual tension. Br J Obstet Gynaecol. 1987;94:30-34.
181. O'Brien PM, Abukhalil IE. Randomized controlled trial of the management of premenstrual syndrome and premenstrual mastalgia using luteal phase-only danazol. Am J Obstet Gynecol. 1999; 180(1, pt 1):18-23.
182. Gorins A, Perret F, Tournant B, Rogier C, Lipszyc J. A French double-blind crossover study (danazol versus placebo) in the treatment of severe fibrocystic breast disease. Eur J Gynaecol Oncol. 1984;5:85-89.
183. Sutton GL, O'Malley VP. Treatment of cyclical mastalgia with low dose short term danazol. Br J Clin Pract. 1986;40:68-70.
184. Peters F, Reck G, Zimmermann G, Breckwoldt M. The effect of danazol on the pituitary function, thyroid function, and mastodynia. Arch Gynecol. 1980;230:3-8.
185. Baker HW, Snedecor PA. Clinical trial of danazol for benign breast disease. Am Surg. 1979;45:727-729.
186. Greenblatt B, Ben-Nun I. Danazol in the treatment of mammary dysplasia. Drugs. 1980;19:349-355.
187. Doberl A, Tobiassen T, Rasmussen T. Treatment of recurrent cyclical mastodynia in patients with fibrocystic breast disease: a double-blind placebo-controlled study - the Hjorring project. Acta Obstet Gynecol Scand Suppl. 1984;123:177-184.
188. Tobiassen T, Rasmussen T, Doberl A, Rannevik G. Danazol treatment of severely symptomatic fibrocystic breast disease and long-term follow-up - the Hjorring project. Acta Obstet Gynecol Scand Suppl. 1984;123:159-176.
189. Maddox PR, Harrison BJ, Mansel RE. Low-dose danazol for mastalgia. Br J Clin Pract Suppl. 1989;68:43-47.
190. Harrison BJ, Maddox PR, Mansel RE. Maintenance therapy of cyclical mastalgia using low-dose danazol. J R Coll Surg Edinb. 1989;34:79-81.
191. Ouimet-Oliva D, Van Campenhout J, Hebert G, Ladouceur J. Effect of danazol on the radiographic density of breast parenchyma. J Can Assoc Radiol. 1981;32:159-161.
192. Dawood MY, Obasiolu CW, Ramos J, Khan-Dawood FS. Clinical, endocrine, and metabolic effects of two doses of gestrinone in treatment of pelvic endometriosis. Am J Obstet Gynecol. 1997; 176:387-394.
193. Peters F. Multicentre study of gestrinone in cyclical breast pain. Lancet. 1992;339:205-208.
194. Mansel RE, Dogliotti L. European multicentre trial of bromocriptine in cyclical mastalgia. Lancet. 1990;335:190-193.
195. Mansel RE, Preece PE, Hughes LE. A double blind trial of the prolactin inhibitor bromocriptine in painful benign breast disease. Br J Surg. 1978;65:724-727.
196. Nazli K, Syed S, Mahmood MR, Ansari F. Controlled trial of the prolactin inhibitor bromocriptine (Parlodel) in the treatment of severe cyclical mastalgia. Br J Clin Pract. 1989;43:322-327.
197. Durning P, Sellwood RA. Bromocriptine in severe cyclical breast pain. Br J Surg. 1982;69:248-249.
198. Schulz KD, Del Pozo E, Lose KH, Kunzig HJ, Geiger W. Successful treatment of mastodynia with the prolactin inhibitor bromocryptine (CB 154). Arch Gynakol. 1975;220:83-87.
199. Parlati E, Polinari U, Salui G, et al. Bromocriptine for treatment of benign breast disease: a double-blind clinical trial versus placebo. Acta Obstet Gynecol Scand. 1987;66:483-488.
200. Palmer BV, Monteiro JC. Bromocriptine for severe mastalgia [letter]. BMJ. 1977;1:1083.
201. Blichert-Toft M, Anderson AN, Henriksen OB, Mygind T. Treatment of mastalgia with bromocriptine: a double-blind cross-over study. BMJ. 1979;1:237.
202. Rea N, Bove F, Gentile A, Parmeggiani U. Prolactin response to thyrotropin-releasing hormone as a guideline for cyclical mastalgia treatment. Minerva Med. 1997;88:479-487.
203. Kumar S, Mansel RE, Hughes LE, Edwards CA, Scanlon MF. Prediction of response to endocrine therapy in pronounced cyclical mastalgia using dynamic tests of prolactin release. Clin Endocrinol (Oxf). 1985;23:699-704.
204. Hinton CP, Bishop HM, Holliday HW, Doyle PJ, Blamey RW. A double-blind controlled trial of danazol and bromocriptine in the management of severe cyclical breast pain. Br J Clin Pract. 1986; 40:326-330.
205. Ioannidou-Mouzaka L, Niagassas M, Galanos A, Kalovidouris A. Pilot study on the treatment of cyclical mastodynia with Quinagolide. Eur J Gynaecol Oncol. 1999;20:117-121.
206. Kaleli S, Aydin Y, Erel CT, Colgar U. Symptomatic treatment of premenstrual mastalgia on premenopausal women with lisuride maleate: a double-blind placebo-controlled randomized study. Fertil Steril. 2001;75:718-723.
207. Fentiman IS, Caleffi M, Brame K, Chaudary MA, Hayward JL. Double-blind controlled trial of tamoxifen therapy for mastalgia. Lancet. 1986;1:287-288.
208. Powles TJ, Ford HT, Gazet J-C. A randomized trial to compare tamoxifen with danazol for treatment of benign mammary dysplasia. Breast Dis Senologia. 1987;2:1-5.
209. Messinis IE, Lolis D. Treatment of premenstrual mastalgia with tamoxifen. Acta Obstet Gynecol Scand. 1988;67:307-309.
210. GEMB Group (Grupo de Estudio de Mastopatias Benignas), Argentine. Tamoxifen therapy for cyclical mastalgia: dose randomized trial. Breast. 1997;5:212-213.
211. Kontostolis E, Stefanidis K, Navrozoglou I, Lolis D. Comparison of tamoxifen with danazol for treatment of cyclical mastalgia. Gynecol Endocrinol. 1997;11:393-397.
212. Sandrucci S, Mussa A, Festa V. Comparison of tamoxifen and bromocriptine in management of fibrocystic breast disease: a randomized blind study. Ann N Y Acad Sci. 1990;586:626-628.
213. Blue J, Harman J. Mastalgia review: St Marks Breast Centre. N Z Med J. 1998;111:33-34.
214. Caleffi M, Fentiman IS, Clark GM, et al. Effect of tamoxifen on oestrogen binding, lipid and lipoprotein concentrations and blood clotting parameters in premenopausal women with breast pain. J Endocrinol. 1988;119:335-339.
215. Fentiman IS, Caleffi M, Rodin A, Murby B, Fogelman I. Bone mineral content of women receiving tamoxifen for mastalgia. Br J Cancer. 1989;60:262-264.
216. Fisher B, Constantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-1388.
217. Cuzick J, Forbes J, Edwards R, et al, IBIS Investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002;360:817-824.
218. Sismondi P, Biglia N, Giai M, Defabiani E. GnRH analogs in benign breast disease and breast cancer chemoprevention: a challenge for the year 2000. Eur J Gynaecol Oncol. 1994;15:108-114.
219. Minjarez DA, Schlaff WD. Update on the medical treatment of endometriosis. Obstet Gynecol Clin North Am. 2000;27:641-651.
220. Hamed H, Caleffi M, Chaudary MA, Fentiman IS. LHRH analogue for treatment of recurrent and refractory mastalgia. Ann R Coll Surg Engl. 1990;72:221-224.
221. Klijn JG, van Geel B, de Jong FH, Sandow J, Krauss B. The relation between pharmacokinetics and endocrine effects of buserelin implants in patients with mastalgia. Clin Endocrinol (Oxf). 1991;34:253-258.
222. Surrey ES, Add-Back Consensus Working Group. Add-back therapy and gonadotropin-releasing hormone agonists in the treatment of patients with endometriosis: can a consensus be reached? Fertil Steril. 1999;71:420-424.
223. Chadbourne EB, Zhang S, Gordon MJ, et al. Clinical outcomes in reduction mammaplasty: a systematic review and meta-analysis of published studies. Mayo Clin Proc. 2001;76:503-510.
224. Blomqvist L, Eriksson A, Brandberg Y. Reduction mammaplasty provides long-term improvement in health status and quality of life. Plast Reconstr Surg. 2000;106:991-997.